Xoma Completes Acquisition of Lava Therapeutics

Acquisition Details: XOMA Royalty has completed the acquisition of all outstanding shares of LAVA Therapeutics, with shareholders receiving $1.04 in cash per share and a contingent value right for additional payments based on future proceeds.

Shareholder Participation: A total of 23,956,708 shares, representing approximately 91.1% of outstanding shares, were tendered in the acquisition, leading to a corporate reorganization.

Post-Acquisition Actions: Following the acquisition, LAVA will undergo a corporate reorganization, and all remaining shareholders will receive the same cash and contingent value right as those in the tender offer.

Trading Suspension: Public trading of LAVA shares was suspended prior to November 21, 2025, with plans for delisting from Nasdaq and deregistration under the Securities Exchange Act.